F8 and hemophilia A: Hemophilia A (HA) is a congenital blood disorder caused by a deficiency or dysfunction of coagulation factor (F)VIII.1Historically, people with HA (PwHA) were treated with recombinant FVIII products or plasma-derived concentrates; however, up to 30% of people with severe HA develop FVIII inhibitors, rendering FVIII replacement therapy ineffective.2Treatment options for PwHA with FVIII inhibitors include activated prothrombin complex concentrate (aPCC) and recombinant activated FVII (rFVIIa), known as bypassing agents (BPAs).2, 3